221 related articles for article (PubMed ID: 23456655)
1. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.
Nakamizo S; Sasayama T; Shinohara M; Irino Y; Nishiumi S; Nishihara M; Tanaka H; Tanaka K; Mizukawa K; Itoh T; Taniguchi M; Hosoda K; Yoshida M; Kohmura E
J Neurooncol; 2013 May; 113(1):65-74. PubMed ID: 23456655
[TBL] [Abstract][Full Text] [Related]
2. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
[TBL] [Abstract][Full Text] [Related]
3. Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors.
Ballester LY; Lu G; Zorofchian S; Vantaku V; Putluri V; Yan Y; Arevalo O; Zhu P; Riascos RF; Sreekumar A; Esquenazi Y; Putluri N; Zhu JJ
Acta Neuropathol Commun; 2018 Aug; 6(1):85. PubMed ID: 30170631
[TBL] [Abstract][Full Text] [Related]
4. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
[TBL] [Abstract][Full Text] [Related]
5. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
6. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
7. Multi-pronged proteomic analysis to study the glioma pathobiology using cerebrospinal fluid samples.
Gahoi N; Malhotra D; Moiyadi A; Varma SG; Gandhi MN; Srivastava S
Proteomics Clin Appl; 2018 May; 12(3):e1700056. PubMed ID: 28679024
[TBL] [Abstract][Full Text] [Related]
8. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.
Zhao H; Heimberger AB; Lu Z; Wu X; Hodges TR; Song R; Shen J
Oncotarget; 2016 Apr; 7(15):20486-95. PubMed ID: 26967252
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
11. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated macrophage related interleukin-6 in cerebrospinal fluid as a prognostic marker for glioblastoma.
Hori T; Sasayama T; Tanaka K; Koma YI; Nishihara M; Tanaka H; Nakamizo S; Nagashima H; Maeyama M; Fujita Y; Yokozaki H; Hirose T; Kohmura E
J Clin Neurosci; 2019 Oct; 68():281-289. PubMed ID: 31327593
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Metabolomic Analysis of IDH1
Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
[TBL] [Abstract][Full Text] [Related]
14. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative
Unterrainer M; Fleischmann DF; Vettermann F; Ruf V; Kaiser L; Nelwan D; Lindner S; Brendel M; Wenter V; Stöcklein S; Herms J; Milenkovic VM; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1368-1380. PubMed ID: 31486876
[TBL] [Abstract][Full Text] [Related]
15. Frequent Diagnostic Under-Grading in Isocitrate Dehydrogenase Wild-Type Gliomas due to Small Pathological Tissue Samples.
Gutt-Will M; Murek M; Schwarz C; Hewer E; Vulcu S; Beck J; Raabe A; Schucht P
Neurosurgery; 2019 Nov; 85(5):689-694. PubMed ID: 30335178
[TBL] [Abstract][Full Text] [Related]
16. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas.
Shen F; Zhang Y; Yao Y; Hua W; Zhang HS; Wu JS; Zhong P; Zhou LF
Neurosurg Rev; 2014 Jul; 37(3):367-80; discussion 380. PubMed ID: 24781189
[TBL] [Abstract][Full Text] [Related]
18. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
[TBL] [Abstract][Full Text] [Related]
19. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
20. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
